Pioneering Science for Patient Choice
Advancing new oral alternatives for all people living with hereditary angioedema (HAE)
Pharvaris is committed to improving the treatment of HAE and the quality of life for people living with HAE through our innovative research, discovery, development, and manufacturing of novel therapeutics
learn about our clinical trials
oral on-demand treatment study
extension study of oral on-demand treatment
oral prophylactic treatment study
We aim to treat all clinical signs of HAE attacks and prevent the occurrence of attacks
Our Scientific Approach:
Bradykinin B2 Receptor antagonists
Our Pipeline:
Orally available small molecules